Oxford University Study Reveals Fosamax Use May Double Risk Of Developing Esophageal Cancer
Get Legal Help Today
Secured with SHA-256 Encryption
UPDATED: Jul 16, 2021
It’s all about you. We want to help you make the right legal decisions.
We strive to help you make confident insurance and legal decisions. Finding trusted and reliable insurance quotes and legal advice should be easy. This doesn’t influence our content. Our opinions are our own.
Editorial Guidelines: We are a free online resource for anyone interested in learning more about legal topics and insurance. Our goal is to be an objective, third-party resource for everything legal and insurance related. We update our site regularly, and all content is reviewed by experts.
Fosamax users, already worried about developing osteonecrosis of the jaw (ONJ) and femur fractures, now have something else to worry about. A new study from the Britain’s Oxford University revealed that Fosamax use may double the risk of developing esophageal cancer.
Fosamax Lawsuits: Esophageal Cancer New Worry
Researchers at Oxford University studied the medical records of more than 6 million people over a 10 year period from 1995 to 2005. What they found was startling. Patients who took bisphosphonate osteoporosis drugs such as Merck & Company’s Fosamax (alendronate), Proctor & Gamble’s Actonel (risedronate) and Didronel (etidronate) and Roche’s Boniva (ibandronate) for five years or more had double the risk of developing esophageal cancer – cancer of the esophagus.
What Is Esophageal Cancer?
Esophageal cancer usually leads to difficulty and pain in swallowing. While chemotherapy and radiotherapy may help, the prognosis of esophageal cancer – depending upon the stage of the cancer and other medical problems – is often poor. That’s because, according to CR Magazine, most people are not diagnosed with esophageal cancer until it’s in later stages – which is mainly due to symptoms not developing until nearly half of the esophagus is obstructed due to tumor growth. This painful form of cancer has already been linked to bisphosphonates
Fosamax Lawsuits: Oxford Study Mirrors FDA Concerns
The U.S. Food & Drug Administration (FDA) reported in the New England Journal of Medicine (NEJM) that 23 patients taking Fosamax have developed esophageal tumors and that eight of those people died. It’s clear that esophageal cancer must now be added to the list of Fosamax side effects and risks.
Fosamax Lawsuits: Hiring A Fosamax Lawyer
If you’ve developed esophageal cancer, osteonecrosis of the jaw or femur fractures and have taken Fosamax or another bisphosphonate osteoporosis drug, contact an experienced Fosamax lawyer to discuss your situation. Fosamax lawsuits have been ongoing for many years and an experienced Fosamax lawyer will understand which arguments, venues and strategies might work best in your situation.